2. Search Result
Search Result
Results for "

Reduced systemic toxicity

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13679
    Sodium 2-mercaptoethanesulfonate
    2 Publications Verification

    Mesnum

    		 Glutathione Peroxidase Cancer
    Mesna (Sodium 2-mercaptoethanesulfonate) is an antioxidant which has cytoprotective effects. Mesna is widely used as a systemic protective agent against chemotherapy toxicity. Mesna is also used to reduce hemorrhagic cystitis induced by cyclophosphamide .
    Sodium 2-mercaptoethanesulfonate
  • HY-164288
    TDI-6570

    TDI-006570

    		 Cyclic GMP-AMP Synthase STING Neurological Disease Inflammation/Immunology
    TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases .
    TDI-6570
  • HY-179392
    Sunitinib-platinum(IV) prodrug-1

    		Apoptosis DNA Alkylator/Crosslinker VEGFR PDGFR Cancer
    Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Pt(IV) prodrug based on Cisplatin (HY-17394), and this design aims to enable Pt(IV) to be reduced to active Pt(II) under intracellular reducing conditions, while simultaneously releasing a derivative of Sunitinib (HY-10255A) with tyrosine kinase inhibitor (TKI) activity. Sunitinib-platinum(IV) prodrug-1 exhibits excellent cytotoxicity against renal cell carcinoma (RCC), causing DNA crosslinking and apoptosis. Sunitinib-platinum(IV) prodrug-1 inhibits the VEGFR/PDGFR signaling pathway, suppressing tumor growth and angiogenesis. Sunitinib-platinum(IV) prodrug-1 can be used for research on renal cell carcinoma .
    Sunitinib-platinum(IV) prodrug-1
  • HY-13679R
    Sodium 2-mercaptoethanesulfonate (Standard)

    Mesnum (Standard)

    		 Glutathione Peroxidase Reference Standards Cancer
    Sodium 2-mercaptoethanesulfonate (Standard) is the analytical standard of Sodium 2-mercaptoethanesulfonate. This product is intended for research and analytical applications. Mesna (Sodium 2-mercaptoethanesulfonate) is an antioxidant which has cytoprotective effects. Mesna is widely used as a systemic protective agent against chemotherapy toxicity. Mesna is also used to reduce hemorrhagic cystitis induced by cyclophosphamide .
    Sodium 2-mercaptoethanesulfonate (Standard)
  • HY-13679S
    2-Mercaptoethanesulfonate-d4 sodium

    Mesnum-d4 sodium

    		 Isotope-Labeled Compounds Glutathione Peroxidase Cancer
    2-Mercaptoethanesulfonate-d4 sodium (Mesnum-d4 sodium) is the deuterium labeled Sodium 2-mercaptoethanesulfonate (HY-13679). Mesna (Sodium 2-mercaptoethanesulfonate) is an antioxidant which has cytoprotective effects. Mesna is widely used as a systemic protective agent against chemotherapy toxicity. Mesna is also used to reduce hemorrhagic cystitis induced by cyclophosphamide .
    2-Mercaptoethanesulfonate-d4 sodium
  • HY-178028
    PRMT5-IN-53

    		Histone Methyltransferase Cancer
    PRMT5-IN-53 is a gut-restricted and orally active PRMT5 inhibitor with pIC50s of ≥ 9.7 against hPRMT5 and mPRMT5. PRMT5-IN-53 binds to the PRMT5:MEP50 complex with a KD of 11.3 pM. PRMT5-IN-53 effectively inhibits PRMT5 locally in the intestines of mice, significantly reducing the number and area of polyps, while avoiding systemic hematological toxicity (such as anemia, neutropenia). PRMT5-IN-53 can be used for the study of colorectal cancer especially for familial adenomatous polyposis (FAP) .
    PRMT5-IN-53
  • HY-139719
    IMD-biphenylC

    		NF-κB Inflammation/Immunology
    IMD-biphenylC is a novel imidazoquinolinone-NF-κB immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.
    IMD-biphenylC
  • HY-139718
    IMD-biphenylB

    		NF-κB Inflammation/Immunology
    IMD-biphenylB is a potent imidazoquinolinone-NF-κB immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.
    IMD-biphenylB
  • HY-117630
    RB-6145

    		Drug Intermediate Cancer
    RB-6145 is an orally active pro-drug of the hypoxic cell radiosensitizer RSU 1069. RB-6145 acts a hypoxic cell radiosensitizer and cytotoxin but reduces systemic toxicity in mice .
    RB-6145
  • HY-185398
    Amikacin liposome

    Amikacin disulfate liposome; Liposomal amikacin

    		 Liposome Antibiotic Bacterial Infection
    Amikacin liposome is a liposome-encapsulated form of Amikacin disulfate (HY-B0509B), an aminoglycoside antibiotic with antibactericidal avtivity. Amikacin liposome prolongs the release of amikacin in the lungs and reduces systemic exposure, thereby lowering systemic toxicity.
    Amikacin liposome
  • HY-179394
    Immunoproteasome-IN-2

    		Proteasome Inflammation/Immunology
    Immunoproteasome-IN-2 is selective immunoproteasome inhibitor with IC50 = 232.3 nM for LMP7, IC50 = 9384.9 nM for β5. Immunoproteasome-IN-2 exhibits ancillary inhibitory activity against LMP2 and MECL-1 subunits. Immunoproteasome-IN-2 demonstrates anti-inflammatory efficacy in a mouse model of arthritis and shows a favorable safety profile in toxicological studies with reduced hepatotoxicity and hematotoxicity. Immunoproteasome-IN-2 has LMP7/β5 selectivity directly correlated with lower systemic toxicity. Immunoproteasome-IN-2 can be employed for research in arthritis .
    Immunoproteasome-IN-2
  • HY-179501
    PDK1-IN-5

    		PDK-1 Reactive Oxygen Species (ROS) Apoptosis Oxidative Phosphorylation Cancer
    PDK1-IN-5 is a selective PDK1 inhibitor. PDK1-IN-5 activaties PDH by diminishing phosphorylation level via PDK1 inhibition. PDK1-IN-5 effectively reverses the Warburg effect and shifts cellular energy metabolism from glycolysis toward oxidative phosphorylation by increased acetyl-CoA, reduced lactate, elevated mitochondrial ROS, and subsequent induction of apoptosis. PDK1-IN-5 robustly inhibits tumor growth in vivo without inducing systemic toxicity. PDK1-IN-5 can be used for lung adenocarcinoma, human non-small cell lung adenocarcinoma and gastric colorectal .
    PDK1-IN-5
  • HY-182360
    Cytisine-platinum(IV) prodrug-1

    		PERK Eukaryotic Initiation Factor (eIF) Bcl-2 Family Apoptosis Reactive Oxygen Species (ROS) STING DNA/RNA Synthesis PD-1/PD-L1 Cancer
    Cytisine-Platinum(IV) Prodrug-1 is a Pt(IV) prodrug incorporating the natural compound Cytisine (HY-N0175) with antiproliferative activity against tumor cells. Cytisine-Platinum(IV) Prodrug-1 promotes calcium transfer across the IP3R1-GRP75-VDAC1 axis to drive mitochondrial calcium overload. Cytisine-Platinum(IV) Prodrug-1 initiates unfolded protein response via PERK, eIF2α, ATF4, and CHOP to modulate Bcl-2 and Bax, triggering apoptosis. Cytisine-Platinum(IV) Prodrug-1 induces mitochondrial dysfunction, ROS production, reduced ATP synthesis, DNA damage, and S-phase cell cycle arrest. Cytisine-Platinum(IV) Prodrug-1 activates the cGAS-STING pathway, reduces PD-L1 expression, drives immunogenic cell death. Cytisine-Platinum(IV) Prodrug-1 exhibits high physiological stability, efficient cellular accumulation, and enhanced platinum-DNA binding, and inhibits tumor growth in mouse models with reduced systemic toxicity. Cytisine-Platinum(IV) Prodrug-1 can be used for the research of lung cancer .
    Cytisine-platinum(IV) prodrug-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: